Developing blood-brain barrier arterial spin labelling as a non-invasive early biomarker of Alzheimer's disease (DEBBIE-AD): a prospective observational multicohort study protocol.

Autor:	Padrela B; Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands b.estevespadrela@amsterdamumc.nl., Mahroo A; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany., Tee M; National University Health System, Singapore., Sneve MH; Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway., Moyaert P; Lawson Health Research Institute, London, Ontario, Canada.; Department of Diagnostic Sciences, University Hospital Ghent, Gent, Belgium., Geier O; Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, Norway., Kuijer JPA; Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands., Beun S; Department of Diagnostic Sciences, University Hospital Ghent, Gent, Belgium., Nordhøy W; Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, Norway., Zhu YD; Biomedical Engineering, University of California Davis, Davis, California, USA., Buck MA; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany.; University of Bremen, Bremen, Germany., Hoinkiss DC; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany., Konstandin S; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany., Huber J; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany., Wiersinga J; Department of Internal Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands., Rikken R; Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands., de Leeuw D; Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands., Grydeland H; Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway., Tippett L; The University of Auckland School of Psychology, Auckland, New Zealand., Cawston EE; The University of Auckland Department of Pharmacology and Clinical Pharmacology, Auckland, New Zealand., Ozturk-Isik E; Bogazici University Institute of Biomedical Engineering, Istanbul, Turkey., Linn J; Department of Neurology, Faculty of Medicine, Babylon, Iraq.; Department of Neurology, Technische Universität Dresden, Dresden, Germany., Brandt M; Department of Neurology, Faculty of Medicine, Babylon, Iraq.; Department of Neurology, Technische Universität Dresden, Dresden, Germany., Tijms BM; Neurology, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands., van de Giessen EM; Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands., Muller M; Department of Internal Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands., Fjell A; Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway.; Oslo University Hospital, Oslo, Norway., Walhovd K; Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway.; Oslo University Hospital, Oslo, Norway., Bjørnerud A; Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway.; Oslo University Hospital, Oslo, Norway., Pålhaugen L; Department of Neurology, Akershus University Hospital, Lorenskog, Norway.; University of Oslo, Oslo, Norway., Selnes P; Department of Neurology, Akershus University Hospital, Lorenskog, Norway., Clement P; Department of Diagnostic Sciences, University Hospital Ghent, Gent, Belgium., Achten E; Department of Diagnostic Sciences, University Hospital Ghent, Gent, Belgium., Anazodo U; Lawson Health Research Institute, London, Ontario, Canada., Barkhof F; Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands.; University College London, London, UK., Hilal S; National University Health System, Singapore.; Department of Pharmacology, National University of Singapore, Singapore., Fladby T; Department of Neurology, Akershus University Hospital, Lorenskog, Norway.; University of Oslo, Oslo, Norway., Eickel K; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany.; University of Applied Sciences Bremerhaven, Bremerhaven, Germany., Morgan C; The University of Auckland School of Psychology, Auckland, New Zealand., Thomas DL; Department of Brain Repair and Rehabilitation, University College London, London, UK., Petr J; Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands.; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany., Günther M; Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany.; University of Bremen, Bremen, Germany., Mutsaerts HJMM; Department of Radiology and Nuclear Medicine, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2024 Mar 08; Vol. 14 (3), pp. e081635. Date of Electronic Publication: 2024 Mar 08.
DOI:	10.1136/bmjopen-2023-081635
Abstrakt:	Introduction: Loss of blood-brain barrier (BBB) integrity is hypothesised to be one of the earliest microvascular signs of Alzheimer's disease (AD). Existing BBB integrity imaging methods involve contrast agents or ionising radiation, and pose limitations in terms of cost and logistics. Arterial spin labelling (ASL) perfusion MRI has been recently adapted to map the BBB permeability non-invasively. The DEveloping BBB-ASL as a non-Invasive Early biomarker (DEBBIE) consortium aims to develop this modified ASL-MRI technique for patient-specific and robust BBB permeability assessments. This article outlines the study design of the DEBBIE cohorts focused on investigating the potential of BBB-ASL as an early biomarker for AD (DEBBIE-AD). Methods and Analysis: DEBBIE-AD consists of a multicohort study enrolling participants with subjective cognitive decline, mild cognitive impairment and AD, as well as age-matched healthy controls, from 13 cohorts. The precision and accuracy of BBB-ASL will be evaluated in healthy participants. The clinical value of BBB-ASL will be evaluated by comparing results with both established and novel AD biomarkers. The DEBBIE-AD study aims to provide evidence of the ability of BBB-ASL to measure BBB permeability and demonstrate its utility in AD and AD-related pathologies. Ethics and Dissemination: Ethics approval was obtained for 10 cohorts, and is pending for 3 cohorts. The results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. Competing Interests: Competing interests: FB is a consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen, Combinostics, and has research agreements with Merck, Biogen, GE Healthcare, Roche. All other authors report no disclosures. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu